These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 29933078)
1. Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: In vitro proof-of-concept. Khoshtinat Nikkhoi S; Rahbarizadeh F; Ahmadvand D; Moghimi SM Eur J Pharm Sci; 2018 Sep; 122():42-50. PubMed ID: 29933078 [TBL] [Abstract][Full Text] [Related]
2. Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin. Farasat A; Rahbarizadeh F; Ahmadvand D; Ranjbar S; Khoshtinat Nikkhoi S J Liposome Res; 2019 Mar; 29(1):53-65. PubMed ID: 29621912 [TBL] [Abstract][Full Text] [Related]
3. Oligo-clonal nanobodies as an innovative targeting agent for cancer therapy: New biology and novel targeting systems. Nikkhoi SK; Rahbarizadeh F; Ahmadvand D Protein Expr Purif; 2017 Jan; 129():115-121. PubMed ID: 27693491 [TBL] [Abstract][Full Text] [Related]
5. Expression and In Vitro Function of Anti-Breast Cancer Llama-Based Single Domain Antibody VHH Expressed in Tobacco Plants. Park SR; Lee JH; Kim K; Kim TM; Lee SH; Choo YK; Kim KS; Ko K Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32079309 [TBL] [Abstract][Full Text] [Related]
6. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319 [TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Gao J; Zhong W; He J; Li H; Zhang H; Zhou G; Li B; Lu Y; Zou H; Kou G; Zhang D; Wang H; Guo Y; Zhong Y Int J Pharm; 2009 Jun; 374(1-2):145-52. PubMed ID: 19446771 [TBL] [Abstract][Full Text] [Related]
9. A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab's epitope with versatile biochemical, biological, and medical applications. Nikkhoi SK; Heydarzadeh H; Vandavasi VG; Yang G; Louro P; Polunas M; Owji H; Hatefi A Immunol Res; 2024 Feb; 72(1):103-118. PubMed ID: 37632647 [TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of camelid single-domain antibodies against HER2. Hussack G; Raphael S; Lowden MJ; Henry KA BMC Res Notes; 2018 Dec; 11(1):866. PubMed ID: 30518413 [TBL] [Abstract][Full Text] [Related]
11. Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Rahbarizadeh F; Rasaee MJ; Forouzandeh M; Allameh AA Mol Immunol; 2006 Feb; 43(5):426-35. PubMed ID: 16337485 [TBL] [Abstract][Full Text] [Related]
12. Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery. Kijanka M; Warnders FJ; El Khattabi M; Lub-de Hooge M; van Dam GM; Ntziachristos V; de Vries L; Oliveira S; van Bergen En Henegouwen PM Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1718-29. PubMed ID: 23778558 [TBL] [Abstract][Full Text] [Related]
13. Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease. Rotman M; Welling MM; Bunschoten A; de Backer ME; Rip J; Nabuurs RJ; Gaillard PJ; van Buchem MA; van der Maarel SM; van der Weerd L J Control Release; 2015 Apr; 203():40-50. PubMed ID: 25668771 [TBL] [Abstract][Full Text] [Related]
14. Phospholipase-Cγ1 Signaling Protein Down-Regulation by Oligoclonal-VHHs based Immuno-Liposome: A Potent Metastasis Deterrent in HER2 Positive Breast Cancer Cells. Asadpour O; Rahbarizadeh F Cell J; 2020 Apr; 22(1):30-39. PubMed ID: 31606964 [TBL] [Abstract][Full Text] [Related]
15. VHH characterization.Recombinant VHHs: Production, characterization and affinity. Chabrol E; Stojko J; Nicolas A; Botzanowski T; Fould B; Antoine M; Cianférani S; Ferry G; Boutin JA Anal Biochem; 2020 Jan; 589():113491. PubMed ID: 31676284 [TBL] [Abstract][Full Text] [Related]
16. Specific drug delivery efficiently induced human breast tumor regression using a lipoplex by non-covalent association with anti-tumor antibodies. Lin YL; Tsai NM; Chen CH; Liu YK; Lee CJ; Chan YL; Wang YS; Chang YC; Lin CH; Huang TH; Wang CC; Chi KH; Liao KW J Nanobiotechnology; 2019 Feb; 17(1):25. PubMed ID: 30728015 [TBL] [Abstract][Full Text] [Related]
17. The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1. Liu L; Wang W; Matz J; Ye C; Bracq L; Delon J; Kimata JT; Chen Z; Benichou S; Zhou P J Virol; 2016 Dec; 90(23):10642-10659. PubMed ID: 27654286 [TBL] [Abstract][Full Text] [Related]
18. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Kirpotin DB; Drummond DC; Shao Y; Shalaby MR; Hong K; Nielsen UB; Marks JD; Benz CC; Park JW Cancer Res; 2006 Jul; 66(13):6732-40. PubMed ID: 16818648 [TBL] [Abstract][Full Text] [Related]
19. Anti-HER2 immunoliposomes for co-delivery of paclitaxel and rapamycin for breast cancer therapy. Eloy JO; Petrilli R; Chesca DL; Saggioro FP; Lee RJ; Marchetti JM Eur J Pharm Biopharm; 2017 Jun; 115():159-167. PubMed ID: 28257810 [TBL] [Abstract][Full Text] [Related]
20. Improved therapeutic activity of HER2 Affibody-targeted cisplatin liposomes in HER2-expressing breast tumor models. Alavizadeh SH; Akhtari J; Badiee A; Golmohammadzadeh S; Jaafari MR Expert Opin Drug Deliv; 2016; 13(3):325-36. PubMed ID: 26578208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]